Recent News

BriaCell Announces Additional Capital Support by the CEO

Berkeley, CA and Vancouver, BC – Aug 2, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, is pleased to announce that Dr. William Williams, BriaCell’s President & CEO, has entered into a non-brokered private placement (the “Offering”) of 4,058,441 units […]